MedTrace Logo

Predicting Dysglycemia in Individuals With Gestational Diabetes Immediately Postpartum Using Continuous Glucose Monitoring

NCT04972955 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 240

Last updated 2025-08-03

No results posted yet for this study

Summary

Gestational diabetes is one of the most common medical disorders in pregnancy and is a major risk factor for the postpartum development of dysglycemia. Despite the high risk of developing dysglycemia, 50-80% of women with gestational diabetes are not receiving testing within a year postpartum. The investigators will conduct a prospective cohort study to examine the use of continuous glucose monitoring immediately postpartum to estimate the risk of maternal dysglycemia postpartum.

Conditions

  • Gestational Diabetes
  • Prediabetes; Complicating Pregnancy
  • Type 2 Diabetes
  • Pregnancy Related
  • Glucose Metabolism Disorders
  • Metabolic Disease
  • Endocrine System Diseases

Interventions

DEVICE

Freestyle Libre 2

Participants will wear a continuous glucose monitoring device, the Freestyle Libre 2, for two weeks following delivery.

DEVICE

Freestyle Libre 2

Participants will wear a second continuous glucose monitoring device, the Freestyle Libre 2, for two weeks at 4-6 months postpartum and before their standard of care postpartum bloodwork after having gestational diabetes.

Sponsors & Collaborators

  • University of Manitoba

    lead OTHER

Principal Investigators

  • Jennifer Yamamoto, MD · University of Manitoba

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-04
Primary Completion
2025-07-25
Completion
2030-12-01

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04972955 on ClinicalTrials.gov